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Aim: To investigate the incidence of human papilloma virus (HPV) types 16, 18 in upper genital tract of women considered at a high risk 
(HR) of developing epithelial ovarian cancer (EOC). Methods: HPV 16 and 18 E6 ORF specific semiquantitative PCR was used to screen 
the incidence of HPV in 20 women at HR of developing EOC and 10 women with no ovarian disease (control). Results: The HR subset 
of fallopian tubes and ovarian tissues showed greater positivity for HPV E6 ORF (40%) as compared to control (10%) tissues. Of all 
the samples, two (10%) were positive for HPV 16, two (10%) were positive for HPV 18, and four (20%) showed positivity for mixed HPV 
16/18 infection. The presence of HPV E6 ORF was found both in the fallopian tubes and ovarian DNA from 6 (30%) patients. In two 
cases (10%) we detected HPV ORF only in the fallopian tube derived genomic DNA. Conclusion: It has been shown the presence of HPV 
in the upper genital tract in women at HR of developing EOC in close proximity of HPV susceptible tissue cervix.
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The devastating and lethal epithelial cancer 
of the ovaries (EOC) is characterized by an asympto-
matic clinical course, the absence of a reliable diag-
nostic marker(s), clearly defined etiologic, pathologic, 
and genetic parameters at an early stage [1, 2]. Vari-
ous lines of evidence point to hormonal, genetic and 
external environment as significant factors in the deve-
lopment of the disease [2, 3]. In addition to the global 
and local environmental factors such as occupational 
exposure, hormones, parity, and age, it is thought 
that there may be a genetic predisposition for deve-
loping EOC [4]. Genetic contribution to cancer risk 
is indica ted by the accumulation of ovarian and breast 
cancers in either a first-degree relatives or a second-
degree relatives in a cohort of women with ovarian 
or/and breast cancers. The most studied risk factor 
for ovarian cancer or breast-ovarian cancer syn-
dromes is an inherited germline mutation of highly 
penetrant DNA repair genes BRCA1 (locus 17q21) and 
BRCA2 (locus 13q12.3). BRCA1 and BRCA2 muta-
tions are responsible for about 5–10% of all ovarian 
cancers. The pe netration of heterozygous BRCA1 and 
BRCA2 mutations are thought to have a dose effect 
dependent upon the mutated allele transcript and 
genetic alterations of tumor suppressor genes, par-
ticularly TP53, in addition to the environmental factors 
mentioned above [5–7].
The genetic and environmental modifiers and 
their synergistic effect on the risk for EOC not associ-
ated with BRCA mutations among women with family 
history of ovarian and breast cancers are subjects 
of active investigation at clinical and molecular level 
[6]. In our previous study, an important DNA repair 
protein in the Fanconi Anemia pathway, Fanconi Ane-
mia complementation protein D2 (FANCD2) has been 
implicated as an important EOC risk factor in women 
without BRCA mutations [7].
HPV is a known etiological moderator of epithelial 
malignancies and has been found in 99.7% of women 
with high-grade cervical intraepithelial neoplasia [8, 9]. 
Even though ovarian tissues reside in close proximity 
of the cervix, the role of HPVs in predisposing women 
for developing EOC has been relatively controversial 
and the prevalence of HPV in EOC varies markedly 
by geographical area [10, 11].
Our present understanding of the productive viral 
infection of HPVs specifies that they are strictly epi-
theliotropic [12]. They infect squamous epithelium and 
establish their genomes as low copy number episomes 
in proliferating basal cells [13]. As infected cells diffe-
rentiate, the viral DNA is amplified to high copy number, 
with concomitant expression of late capsid proteins 
L1 and L3, followed by the encapsidation and release 
of infectious virus particles [14]. The HPV genome gets 
integrated with host cell genome, often accompanied 
by the loss of early viral regulatory genes E1 and E2, 
and a dysregulated expression of E6/E7 gene pro ducts. 
The early viral proteins E6 and E7 directly interact with 
TP53 and PRb and subvert their expression and hence 
act as potent oncogenes. Additionally, E6 and E7 in-
teract with factors affecting growth and apoptosis and 
are critical for neoplastic transformation of the host 
cell [15]. Elevated E6 and E7 protein levels are indica-
tors of growth changes and transform epithelial cells. 
High risk (HR) HPV E6 and E7 oncoproteins can each 
independently induce genomic instability in normal cells 
by generation of mitotic defects and aneuploidy through 
the induction of centrosome abnormalities [16].
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We designed this study to investigate the presence 
of DNA of HPV 16 and 18 in the upper genital tract 
in women at HR of developing EOC.
MATERIALS AND METHODS
Patients samples. 30 samples from Oregon Ova-
rian Cancer Tissue Repository which included 10 nor-
mal ovaries were obtained from women who underwent 
oophorectomy for unrelated causes and 20 fallopian 
tubes and ovaries from HR women undergoing risk 
reducing oophorectomy after having obtained signed 
informed consent. The study was approved by the Ethi-
cal Committee permission of Institute of Experimen-
tal Pathology, Oncology and Radiobiology of NAS 
of Ukraine for studies with human materials.
We define patients considered to be at HR for EOC 
as women with two or more first degree relatives with 
ovarian and/or breast cancer, or with a personal his-
tory of breast cancer along with first-degree relatives 
with breast and/or ovarian cancer. Five HR women 
had mutations in BRCA1 or BRCA2 genes. The mean 
age at the time of oophorectomy for HR patients was 
45.7 ± 2.5 with age ranging from 26 to 74 years and 
prevailing majority of women (12/20; 60%) were aged 
26–46 years.
DNA extraction. Formalin-fixed, paraffin-embed-
ded samples were obtained as 20 μm slices, depa-
raffinized in xylene, rehydrated in absolute and 70% 
ethanol. Vigorous precautions were taken to avoid 
sample contamination, including sample preparation 
of experimental and positive controls in different labs 
and cleansing the microtome with 75% ethanol before 
and after cutting each paraffin block. Then samples 
were processed with QIAamp DNA Mini kit (Qiagen) ac-
cording manufacturers’ instructions. DNA was eluted 
from columns in a volume of 50 μl.
PCR amplification. The quality of DNA from each 
tumor specimens was confirmed by PCR using primers 
for β-globin (224 bp):
β-globin F: CACTCAGTGTGGCAAAGGTGCCC;
β-globin R: GGCACTGACTCTCTCTGCCT.
We detected the presence of HPV genome with 
type-specific primers for E6 fragment of high-risk HPV 
types 16 and 18.
The primers sets were as following:
HPV 16 F: TTAGAATGTGTGTACTGCAAGC;
HPV 16 R: TTGTCCAGATGTCTTTGCTT;
HPV 18 F: CACTTCACTGCAAGACATAG;
HPV 18 R: CTATGTTGTGAAATCGTCGT.
All primers were designed using the Vector NTI 
software (Invitrogen), homology of designed primers 
was tested by BLAST algorithm (NCBI nucleic acid 
database).
All PCR reactions were carried out in a total volume 
of 50 μl. The reaction mixture contained 1×PCR buf-
fer (Promega, USA), 3 mM MgCl2, 0.2 mM each dNTP, 
2.0 μM primers and 1.25u Taq polymerase (Promega, 
USA) and either 30 or 10 ng of DNA. Samples were am-
plified on an ABS programmable thermal cycler (Ap-
plied Biosystems, USA). The mixture was denatured for 
5 min at 92 °C followed by 33 or 37 cycles as follows: 
denaturation at 92 °C for 30 s, annealing at 53 °C for 
30 s, extension at 72 °C for 1 min. The final extension 
was for 10 min at 72 °C. The amplified gene fragments 
281bp for HPV 16 and 326bp for HPV 18 were visualized 
on 2% agarose gels. HeLa and Caski cell lines DNA 
were used as positive control for HPV 16 and 18 ampli-
fication. Water template was used as negative control.
RESULTS
Detection of HPV 16/18 DNA in upper genital 
tract of patients at HR of developing EOC. The pre-
sence of HPV 16 and 18 genomes were detected 
by PCR of E6 ORF using HPV type specific primers 
in fallopian tubes and ovaries samples from a cohort 
of 20 women at HR of developing EOC and 10 con-
trol women. We chose highly specific primers and 
optimized the PCR conditions such that there was 
no cross reactivity with other HPV types and  secondary 
amplifications were absent (data not shown). PCR 
of control material did not suggest the presence 
of confounding factors or contamination. Moreover, 
in all cases, the β-globin gene was clearly amplified, 
indicating an adequate DNA isolation from samples. 
Negative controls consistently yielded no detectable 
bands, whereas positive controls showed distinctive 
bands (Figure).
1
300 bp — HPV 18
β-globin
HPV 16
β-globin
200 bp —
300 bp —
200 bp —
MW - Pos 2 3 4 5 6
1MW -Pos 2 3 4 5 6 7 8 9 10 11
Figure. HPV E6 specific PCR on genomic DNAs isolated 
from formalin fixed and paraffinized fallopian tubes and ova-
rian tissue sections as templates. The products were sepa-
rated on a 2% agarose gel and stained with ethidium bromide. 
The marker is marked as MW; lines 1–4, 6, 7 represent the ampli-
fication products for HPV 16, lower panel. Lines 5, 8–11 represent 
HPV 16 negative samples. Lines 4 and 6 represent amplification 
products for HPV 18, upper panel. Lines 1–3 and 5 represent 
HPV 18 negative samples. The control for each of these samples 
was 224bp β-globin and is shown. Negative control (water for 
PCR) and positive control using genomic DNA either from freshly 
cultured CasKi or HeLa cells are shown
When we analyzed each cohort separately, 
 surprising differences were found. In the control 
patients cohort consisting of 10 samples, only one 
ovarian sample (10%) tested positive for HPV 16, rest 
of the control samples were negative for HPV 18 and 
16 E6 ORF. In the 20 HR persons, a total of 8 (40%) pa-
tients tested positive for HPV 16 and 18 genomes (Ta-
ble). Two patients tested positive for HPV had BRCA 
mutations. Of all the samples, two (10%) were positive 
for HPV 16, two (10%) were positive for HPV 18, and 
four (20%) showed positivity for mixed HPV 16/18 in-
fection. The fallopian tubes and ovaries on separate 
blocks were available for all 20 HR patients. The pre-
sence of HPV E6 ORF was found both in the fallopian 
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tubes and ovarian DNA from 6 (30%) patients. In two 
cases (10%) we detected HPV ORF only in the fallopian 
tube derived genomic DNA.
Table. The frequency of HPV infection types 16 and 18 in the upper geni-
tal tract of women at HR of developing EOC
HPV type HR patients, n (%)
Specimens from HR patients, n (%)
Fallopian tubes Fallopian tubes + ovaries
HPV 16 2 (10.0) 1 (5.0) 1 (5.0)
HPV 18 2 (10.0) 1 (5.0) 1 (5.0)
HPV 16/18 4 (20.0) 0 4 (20.0)
Total 8 (40.0) 2 (10.0) 6 (30.0)
DISCUSSION
The HR HPVs are critical etiologic factors for de-
velopment of malignancies in the lower female genital 
tract [8]. The significance of HR HPVs in upper genital 
tract, including ovarian cancer is controversial. There 
has been variable frequency reported by various 
groups regarding the presence or absence of HPV 
in ovarian tissues and its putative role in cancer de-
velopment [10, 11]. There have also been recurrent 
reports where viral sequences have been detected 
in vessel endothelial cells adjacent to cervical and oral 
cancers [17, 18]. In our previous study, PCR analysis 
demonstrated HPV DNA in 17.0% (9 from 53) ovarian 
serous carcinomas [19]. All HPV 16 and 18 DNA-po-
sitive OC tissues showed immunopositivity for E6 on-
coprotein, which was adjacent to peritumoral area 
and was detected in glandular structures of ovarian 
carcinomas. In our small subset of nine samples that 
tested positive for diffused HPV E6 staining, we ob-
served an acute downmodulation of p53 expression.
Results from this current study show the pre-
sence of HR HPVs in the upper genital tract of women 
at HR of developing EOC. The specific and sensitive 
PCR assay developed in our labs could detect HPV 
DNA derived from a very small number of contribu-
ting cells. The possibility of false positive was ruled 
out with consistent and concordant results among 
cross-technique and biological replicates (left 
or right ovarian tissues and corresponding fallopian 
tubes) and negative controls included in the study. 
Quite interesting ly, we did detect HPV 16, 18 E6 ORF 
in the upper genital tissues of HR cohort in a larger 
proportion compared to previously reported ova rian 
carcinomas [19].  However, one of the limitations 
of this study was the small sample size and therefore 
a higher than previously reported HPV positivity might 
not reflect a true statistical distribution.
It is known that different subtypes of epithelial 
ovarian carcinoma are associated with various genetic 
and environmental risk factors and molecular events 
during oncogenesis [20, 21]. In BRCA carriers can-
cer initiation may occur in the ovary, fallopian tube, 
or peritoneum but tumor growth and progression are 
favored in the ovary [22–24]. These results showing 
the HPV infection clamber through the genital tract 
may probably occur by a nonconventional mechanism 
where endothelial cells possibly acquired whole viral 
particles by phagocytosis and in turn presented them 
to ovarian epithelial cells or other differentiating cells 
of the upper genital tract where additionally to genetic 
factors appears to be possible environmental modifier 
of ovarian cancer risk in women at HR of developing 
EOC. Enhanced opportunistic infectivity in women 
with an inherent greater genomic instability is highly 
possible. There are reports in the literature that Fan-
coni anemia patients have an inherent susceptibility 
to human HPV-associated anogenital malignancies 
including ovarian carcinoma [25, 26]. But we also need 
to unequivocally establish this supposed mechanism 
of HPV transmission in vivo using a three dimensional 
organotypic culture model and genetic instability 
of ovarian epithelial cells causing susceptibility to HPV 
infection. Since our sample size was small, we need 
to further confirm these results in a larger statistically 
significant sample set.
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